{"schema_version":"secwatch.filing_event.v1","accession":"0001365916-23-000034","form_type":"8-K","ticker":null,"cik":"0001365916","company_name":"AMYRIS, INC.","filed_at":"2023-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.576579+00:00","generated_at":"2026-06-17T06:24:49.821773+00:00","sec_items":["2.01","8.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Amyris closes $200M asset sale to Givaudan, buys remaining 49% of Aprinnova for $49M","bullets":["Sold cosmetic ingredients assets to Givaudan for $200M upfront cash plus up to $150M performance earnout over three years.","Total estimated value including near- and long-term manufacturing partnership is approximately $500M.","Purchased 49% of Aprinnova from Nikko Chemicals and Nissa for $49M cash, increasing Amyris ownership to 99%.","Both transactions closed on April 3, 2023, as previously announced.","Long-term partnership with Givaudan for Amyris to manufacture cosmetic ingredients."],"urls":{"canonical":"https://secwatch.observer/filing/0001365916-23-000034","json":"https://secwatch.observer/filing/0001365916-23-000034.json","markdown":"https://secwatch.observer/filing/0001365916-23-000034.md","text":"https://secwatch.observer/filing/0001365916-23-000034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1365916/000136591623000034/0001365916-23-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1365916/000136591623000034/amrs-20230403.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T06:24:49.821773+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"896897f376c31bea77998039f39028cb1bbbf5bd","claim":"AMYRIS, INC. completed a disposition involving Givaudan SA for $200 million upfront cash consideration and up to $150 million in performance-based earnout payments over three years (closed 2023-04-03).","evidence_excerpt":"to distribute, market and sell Neossance® Squalane emollient, Neossance® Hemisqualane silicone alternative and CleanScreenTM sun protector in cosmetics actives, to Givaudan for $200 million upfront cash consideration and up to $150 million in performance-based earnout payments over three years. In addition, the parties entered into a long-term partnership agreement","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1365916/000136591623000034/0001365916-23-000034-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Givaudan SA"},{"label":"Consideration","value":"$200 million upfront cash consideration and up to $150 million in performance-based earnout payments over three years"},{"label":"Closing","value":"2023-04-03"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}